Objective : The cause of severe clinical vasospasm after aneurysmal subarachnoid hemorrhage remains unknown, despite extensive research over the past 30 years. However, the intra-arterial administration of vasodilating agents and balloon angioplasty have been successfully used in severe refractory cerebral vasospasm.
INTRODUCTION
Cerebral vasospasm remains a leading cause of morbidity and mortality following aneurysmal subarachnoid hemorrhage (SAH). 21) Cerebral vasospasm is a prolonged but reversible narrowing of cerebral arteries beginning days after SAH. Progression to cerebral ischemia is tied mostly to vasospasm severity, and its pathogenesis lies in artery encasement by blood clots, although the complex interactions be- (Fig. 1) .
MATERIALS AND METHODS

Location of aneurysms
The most frequent site of aneurysm was the anterior communicating artery, followed by the posterior communicating artery (26.2%) and middle cerebral artery (18.9%) ( Table 2 , Fig. 2 ). The most frequent site of aneurysms in symptomatic vasospasm patients was also anterior communicating artery (37.1%), followed by posterior communicating artery (25.9%) and middle cerebral artery (18.5%) ( Table 3 , Fig. 3 ).
Prognosis
The clinical results are shown in Table 4 . Improvement was observed in 14 (51.9%) patients. Craniectomy was performed in 4 (14.8%). The mortality rate was 11.1%.
The causes of death were pneumonia in 2 patients (7.4%) and acute renal failure in 1 patient (3.7%).
After the patients were followed-up for 3-6 months, favorable outcomes were observed (average modified Rankin scale score: 3.3). No procedure-related complications were observed.
DISCUSSION
Angiographic vasospasm is common after rupture of an aneurysm, with an overall incidence of 50-90%. 9) Vasospasm is rare in the first 2 days after SAH, but increases after the fourth day. 27) In 530 cases, 28) the highest incidence was between days 10 and 17, peaking on day 13 at 60%. In another series, 16) vasospasm Total 27 Acom = anterior communicating artery; Pcom = posterior communicating artery; MCA = middle cerebral artery; ICA = internal carotid artery occurred in a third of patients in the first week and in two-thirds in the second week. Accordingly, it is important to remain vigilant for this complication for at least 2 weeks after SAH. The aim of vasospasm management is to optimize cerebral blood flow in order to prevent delayed cerebral ischemia (DCI).
Medical treatment is usually the initial step when vasospasm is suspected. However, vasospasm is often refractory to these treatments. Moreover, many patients do not tolerate the combination of induced hypertension, hypervolemia, and hemodilution, which is referred to as 'triple-H' therapy, usually due to cardiac and pulmonary complications including myocardial ischemia, congestive heart failure and pulmonary edema. For these patients, early endovascular treatment appears to be the best alternative. Magnesium sulfate (MgSO4) has neuroprotective and vasodilatory properties and has therefore been tested for the prevention of vasospasm and ischemia in patients with SAH. One early study found no benefit from intravenous MgSO4 infusions, 47) another showed a variety of beneficial trends toward benefit, 43) and a third suggested efficacy equivalent to nimodipine in preventing ischemic damage.
40)
CONCLUSION
Endovascular intervention may have an important role in selected cases to reduce vasospasm-related morbidity and mortality after aneurysmal SAH. In our experience, endovascular treatment is safe, with a low complication rate, but further studies are required to determine appropriate patient selection and treatment efficacy.
